Novo Nordisk Foundation, the Gates Foundation and Open Philanthropy are providing an initial $90m to fund more antiviral candidates through to proof-of-concept Phase II studies.
The world needs to better prepared for the next pandemic, including having more novel antivirals ready to go when it strikes, but funding for early discovery and development is currently patchy.
To address this problem, a new Pandemic Antiviral Discovery (PAD) initiative has been set up by three charities, the Novo...
Pfizer/BioNTech and Moderna rapidly adapted Comirnaty and Spikevax for the 2024-2025 season to address the KP.2 variant after the US FDA had advised them to target JN.1 in June.
The companies said their combination mRNA vaccine showed protection against SARS-CoV-2 and influenza A, but not influenza B.
The UK giant’s COVID-19 prophylactic sipavibart could soon reach Europe and competition is sparse.
When life hands a biotech company the equivalent of good grapes, the expectations are for its products to be the equivalent of fine wine. Before that Moderna looks likely to make lemonade.
Lilly's first Phase III triplet win opens the door to a label expansion in BTK-pretreated CLL, with analysts suggesting Jaypica could attain blockbuster status. However, the window to capitalize may be brief as next-generation BTK degraders close in with head-to-head trials.
Mounjaro, Eliquis, and Darzalex buck the Q1 trend to make gains
